Maverick Therapeutics gets R&D support from Takeda; Takeda gets M&A option; Option Exercised
Executive Summary
Maverick Therapeutics Inc. and Takeda Pharmaceutical Co. Ltd. (through its Takeda Oncology/Millennium Pharmaceuticals division) have entered into an agreement to further develop Maverick’s immunotherapies for cancer.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes M&A Option
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice